Page last updated: 2024-11-10

coumestrol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Coumestrol: A daidzein derivative occurring naturally in forage crops which has some estrogenic activity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

coumestrol : A member of the class of coumestans that is coumestan with hydroxy substituents at positions 3 and 9. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281707
CHEMBL ID30707
CHEBI ID3908
SCHEMBL ID22012
MeSH IDM0005259

Synonyms (82)

Synonym
BIDD:ER0114
S00280
smr000059001
MLS000069446
cumostrol
nsc22842 ,
nsc-22842
mls000738006 ,
6h-benzofuro[3, 3,9-dihydroxy-
3-benzofurancarboxylic acid,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone
cumoestrol
NCI60_001863
NCIMECH_000078
OPREA1_222511
cumoesterol
6h-benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-
nsc 22842
einecs 207-525-6
3,9-dihydroxy-6h-benzofuro(3,2-c)(1)benzopyran-6-one
brn 0266702
ccris 7311
3-benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone
3,9-dihydroxy-6h-[1]benzofuro[3,2-c]chromen-6-one
3,9-dihydroxybenzofuro[3,2-c]chromen-6-one
SMP2_000163
coumestrol
479-13-0
NCGC00023462-04
NCGC00023462-03
bdbm23451
5,14-dihydroxy-8,17-dioxatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2,4,6,11(16),12,14-heptaen-9-one
NCGC00018124-01
chembl30707 ,
7,12-dihydroxycoumestan
us8552057, 3
coumestrol, >=95.0% (hplc)
coumestrol, bioreagent, suitable for fluorescence, >=97.5% (hplc)
chebi:3908 ,
cumestrol
LMPK12090018
3,9-dihydroxycoumestan
NCGC00018124-03
NCGC00018124-06
NCGC00018124-02
NCGC00018124-04
NCGC00018124-05
3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one
3,9-dihydroxy-[1]benzoxolo[3,2-c]chromen-6-one
unii-v7nw98ob34
5-19-06-00405 (beilstein handbook reference)
v7nw98ob34 ,
NCGC00257586-01
dtxcid102399
dtxsid6022399 ,
tox21_200032
cas-479-13-0
A827386
HMS2235B05
CCG-36200
CCG-35536
coumesterol
FT-0603177
coumestrol [mi]
HMS3374A07
SCHEMBL22012
A1-00298
3-benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone
6h-benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-
6h-benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihdyroxy-
3,9-dihydroxy-6h-[1]benzofuro[3,2-c]chromen-6-one #
mfcd00016885
AKOS028111776
CS-6343
HY-N2335
coumestrol (cou)
3,9-dihydroxy-6h-benzofuro[3,2-c]chromen-6-one ,
Q908865
BRD-K97509413-001-01-8
D85092
AS-81377
gtpl12437
3,9-dihydroxy-6h-(1)benzofuro(3,2-c)chromen-6-one

Research Excerpts

Overview

Coumestrol is a plant-derived compound that belongs to the class of phytoestrogens, natural compounds that mimic the biological activity of estrogens. It is a natural phytochemical present in plants such as red clover and soy, and has been reported to stimulate the estrogen receptor.

ExcerptReferenceRelevance
"Coumestrol is a phytoestrogen found in various plant foods. "( Coumestrol as a new substance that may diminish lipid precursors of the inflammation in steatotic primary rat hepatocytes.
Bzdęga, W; Chabowski, A; Harasim-Symbor, E; Konstantynowicz-Nowicka, K; Kołakowski, A; Kurzyna, PF; Żywno, H, 2023
)
3.8
"Coumestrol is a potent isoflavonoid with a protective effect against ischemic brain damage in adult rats."( Phytoestrogen coumestrol attenuates brain mitochondrial dysfunction and long-term cognitive deficits following neonatal hypoxia-ischemia.
Anastacio, JBR; Fabres, RB; Netto, CA; Nicola, F; Odorcyk, F; Sanches, EF, 2019
)
1.6
"Coumestrol is a dietary phytoestrogen with estrogen-mimicking characteristics. "( Antiobesity effects of coumestrol through expansion and activation of brown adipose tissue metabolism.
Ahn, SY; Cho, YK; Jeong, HW; Jung, YS; Kim, SN; Kwon, HJ; Lee, YH; Saha, A; Son, Y; Song, HD, 2020
)
2.31
"Coumestrol is a phytoestrogen widely known for its anti-diabetic, anti-oxidant, and anti-inflammatory properties. "( The Influence of Coumestrol on Sphingolipid Signaling Pathway and Insulin Resistance Development in Primary Rat Hepatocytes.
Bzdega, W; Chabowski, A; Harasim-Symbor, E; Kolakowski, A; Konstantynowicz-Nowicka, K; Kurzyna, P; Sztolsztener, K; Zywno, H, 2021
)
2.4
"Coumestrol is a polyphenol with promising therapeutic applications as phytoestrogen, antioxidant and potential cancer chemoprevention agent. "( Phytoestrogen coumestrol: Antioxidant capacity and its loading in albumin nanoparticles.
Arriagada, F; Berríos, E; Bollo, S; Günther, G; Montero, G; Morales, J; Mura, F, 2019
)
2.32
"Coumestrol is a plant-derived compound that belongs to the class of phytoestrogens, natural compounds that mimic the biological activity of estrogens."( Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.
Hsieh, D; Jablons, DM; Liu, S; Peto, C; Xu, Z; Yang, YL; You, L, 2013
)
2.55
"Coumestrol is a common phytoestrogen found in plants and Chinese medicinal herbs. "( Coumestrol inhibits autoantibody production through modulating Th1 response in experimental autoimmune thyroiditis.
Fan, C; Jin, Q; Jin, X; Li, J; Shan, Z; Teng, W; Wang, S; Zhao, X, 2016
)
3.32
"Coumestrol is a natural phytochemical present in plants such as red clover and soy, and has been reported to stimulate the estrogen receptor as a major phytoestrogen. "( Coumestrol modulates Akt and Wnt/β-catenin signaling during the attenuation of adipogenesis.
Ahn, J; Ha, T; Jang, YJ; Jung, CH; Son, HJ, 2016
)
3.32
"Coumestrol is a phytoestrogen present in soybean products and recognized as potential cancer therapeutic agent against breast cancer. "( Cytotoxic activity of soy phytoestrogen coumestrol against human breast cancer MCF-7 cells: Insights into the molecular mechanism.
Naseem, I; Singh, S; Zafar, A, 2017
)
2.17
"Coumestrol is an estrogenic and antioxidant agent, characterized by its low solubility in aqueous and lipophilic media, once in the aglicone form. "( Studies on coumestrol/beta-cyclodextrin association: Inclusion complex characterization.
Bassani, VL; Franco, C; Koester, LS; Lula, I; Schwingel, L; Sinisterra, RD, 2009
)
2.19
"Coumestrol is a naturally occurring plant estrogen. "( The effect of the phytoestrogen coumestrol on the NZB/W F1 murine model of systemic lupus.
Fritzler, MJ; Hart, DA; Pollard, KM; Schoenroth, LJ, 2004
)
2.05
"Coumestrol is a phytoestrogen that can be found in high concentrations in the dietary elements of cattle."( Gonadotrophin levels and morphological testicular features in rats after different doses of the phytoestrogen coumestrol.
Diaz-Sánchez, V; García-Lorenzana, CM; Tarragó-Castellanos, CR; Velázquez-Moctezuma, J, 2006
)
1.27
"Coumestrol is a naturally occurring plant coumarin that displays high affinity for the hormone-binding site of the human estrogen receptor (hER), for which it serves as a potent non-steroidal agonist. "( In situ localization of the estrogen receptor in living cells with the fluorescent phytoestrogen coumestrol.
Miksicek, RJ, 1993
)
1.95

Effects

Coumestrol has long been known as the phytoestrogenic compound in alfalfa. It may prove to be a more potent drug against bone diseases including osteoporosis.

ExcerptReferenceRelevance
"Coumestrol has considerable potential for further development as a novel anti-cancer agent."( Coumestrol Epigenetically Suppresses Cancer Cell Proliferation: Coumestrol Is a Natural Haspin Kinase Inhibitor.
Chen, H; Choi, HK; Dong, Z; Jang, M; Kim, JE; Kim, JH; Lee, KW; Lee, SY; Lim, TG, 2017
)
2.62
"Coumestrol has long been known as the phytoestrogenic compound in alfalfa. "( Phytoestrogenic compounds in alfalfa sprout (Medicago sativa) beyond coumestrol.
Hong, YH; Hsu, C; Huang, CJ; Kuo, YH; Lin, BF; Wang, SC, 2011
)
2.05
"As coumestrol has less estrogenic activity than 17 beta-estradiol, it may prove to be a more potent drug against bone diseases including osteoporosis."( Effect of coumestrol on bone metabolism in organ culture.
Tsutsumi, N, 1995
)
1.21

Actions

Coumestrol promotes cell death in the choriocarcinoma cells by regulating ERK1/2 MAPK and JNK MAPK signaling pathways and through disruption of Ca2+ and ROS homeostasis.

ExcerptReferenceRelevance
"Coumestrol and genistein inhibit ductal branching and alveolar formation by affecting the proliferation and migration of MECs with the induction of apoptosis."( Adverse Effects of Coumestrol and Genistein on Mammary Morphogenesis and Future Milk Production Ability of Mammary Epithelial Cells.
Kobayashi, K; Kumai, A; Nishimura, T; Suzuki, N; Suzuki, T; Tsugami, Y; Wakasa, H, 2020
)
1.61
"Does coumestrol inhibit proliferation of human placental choriocarcinoma cells?"( Coumestrol induces mitochondrial dysfunction by stimulating ROS production and calcium ion influx into mitochondria in human placental choriocarcinoma cells.
Bazer, FW; Jeong, M; Lim, W; Song, G; Yang, C, 2017
)
2.41
"Coumestrol promotes cell death in the choriocarcinoma cells by regulating ERK1/2 MAPK and JNK MAPK signaling pathways and through disruption of Ca2+ and ROS homeostasis."( Coumestrol induces mitochondrial dysfunction by stimulating ROS production and calcium ion influx into mitochondria in human placental choriocarcinoma cells.
Bazer, FW; Jeong, M; Lim, W; Song, G; Yang, C, 2017
)
3.34

Treatment

Coumestrol treatment through the subcutaneous route stimulated uterine growth in OVX mice at a level lower than that of E2. Treatment suppressed MDI-induced protein expression of PPARγ and C/EBPα in adipocytes, leading to the subsequent downregulation of FAS and aP2 expression.

ExcerptReferenceRelevance
"Coumestrol treatment through the subcutaneous route stimulated uterine growth in OVX mice at a level lower than that of E2."( Protective Effects of Coumestrol on Metabolic Dysfunction and Its Estrogen Receptor-Mediated Action in Ovariectomized Mice.
Heo, W; Kim, JH; Park, S; Sim, KS, 2023
)
1.95
"Coumestrol treatment was effective in preventing neuronal loss in all times of administration as well as able to rescue the Na+, K+ -ATPase activity, suggesting its potential benefits for either prevention or therapeutics use against cerebral ischemia in males."( Coumestrol treatment prevents Na+, K+ -ATPase inhibition and affords histological neuroprotection to male rats receiving cerebral global ischemia.
Castro, CC; da Cunha, MJ; Machado, FR; Moura, N; Netto, CA; Pagnussat, AS; Wyse, AT, 2014
)
3.29
"Coumestrol treatment suppressed MDI-induced protein expression of PPARγ and C/EBPα in adipocytes, leading to the subsequent downregulation of FAS and aP2 expression."( Coumestrol modulates Akt and Wnt/β-catenin signaling during the attenuation of adipogenesis.
Ahn, J; Ha, T; Jang, YJ; Jung, CH; Son, HJ, 2016
)
2.6
"Coumestrol treatment induced ROS generation coupled to DNA fragmentation, up-regulation of p53/p21, cell cycle arrest at G1/S phase, mitochondrial membrane depolarization and caspases 9/3 activation."( Cytotoxic activity of soy phytoestrogen coumestrol against human breast cancer MCF-7 cells: Insights into the molecular mechanism.
Naseem, I; Singh, S; Zafar, A, 2017
)
1.44
"Coumestrol treatment did not significantly alter the time of vaginal opening, although vaginal opening did occur at a lighter body weight."( A phytoestrogen diet induces the premature anovulatory syndrome in lactationally exposed female rats.
Lewis, C; Naftolin, F; Whitten, PL, 1993
)
1.01
"Treatment with coumestrol in the state of increased fatty acids availability led to the deposition of triacylglycerols rather than diacylglycerols, significantly decreased expression of proinflammatory and profibrotic cytokines, especially interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), as well as transforming growth factor β (TGF-β), and nuclear factor κβ (NF-κβ)."( Coumestrol as a new substance that may diminish lipid precursors of the inflammation in steatotic primary rat hepatocytes.
Bzdęga, W; Chabowski, A; Harasim-Symbor, E; Konstantynowicz-Nowicka, K; Kołakowski, A; Kurzyna, PF; Żywno, H, 2023
)
2.69
"Upon treatment with coumestrol, trophoblast cells exhibited reduced migration and proliferation."( Coumestrol induces oxidative stress and impairs migration and embryonic growth.
Caron, KM; Douglas, ES; Goodwin, ER; Marbrey, MW, 2023
)
2.67
"Treatment with coumestrol or apigenin had no effect on Ca transport."( The effect of two dietary and a synthetic phytoestrogen on transepithelial calcium transport in human intestinal-like Caco-2 cells.
Cashman, KD; Cotter, AA, 2005
)
0.67

Toxicity

Coumestrol could reverse the toxic effect induced by lipopolysaccharide (LPS) and amyloid-beta peptide.

ExcerptReferenceRelevance
"The current investigations were undertaken to study the mechanism of the adverse effect of phytoestrogens on the function of bovine granulosa (follicles >1< cm in diameter) and luteal cells from day 1-5, 6-10, 11-15, 16-19 of the oestrous cycle."( The adverse effect of phytoestrogens on the synthesis and secretion of ovarian oxytocin in cattle.
Kotwica, J; Mlynarczuk, J; Wrobel, MH, 2011
)
0.37
"Different concentrations of coumestrol were tested for their protective efficacy against two toxic insults, lipopolysaccharide (LPS) and amyloid-beta peptide, on astrocytes."( The protective effects of coumestrol against amyloid-β peptide- and lipopolysaccharide-induced toxicity on mice astrocytes.
Liu, MH; Sheu, SY; Shih, CM; Sun, JS; Tsuang, FY, 2011
)
0.96
" The addition of coumestrol could reverse the toxic effect induced by LPS and amyloid-beta peptide."( The protective effects of coumestrol against amyloid-β peptide- and lipopolysaccharide-induced toxicity on mice astrocytes.
Liu, MH; Sheu, SY; Shih, CM; Sun, JS; Tsuang, FY, 2011
)
1.01

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" The dose-response pattern of enhanced GnRH-induced LH release at lower pretreatment doses but inhibited GnRH-induced LH release at higher pretreatment doses was observed for E2 and genistein."( Effects of phytoestrogens on GnRH-induced luteinizing hormone secretion in ovariectomized rats.
Hughes, CL,
)
0.13
" Neonatal rats were dosed with 10 or 100 micrograms of coumestrol or equol on postnatal day (PND) 1-10."( Methylation profile and amplification of proto-oncogenes in rat pancreas induced with phytoestrogens.
Blann, E; Bo, J; Lyn-Cook, BD; Medlock, K; Payne, PW; Sheehan, D, 1995
)
0.54
" PBK models were developed using a generic approach and in vitro concentration-response data from the MCF-7 proliferation assay and the yeast estrogen screening assay were translated into in vivo dose-response data."( Development of a Generic Physiologically Based Kinetic Model to Predict In Vivo Uterotrophic Responses Induced by Estrogenic Chemicals in Rats Based on In Vitro Bioassays.
Rietjens, IMCM; van Ravenzwaay, B; Zhang, M, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anti-inflammatory agentAny compound that has anti-inflammatory effects.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
coumestansMembers of the class of benzofurochromene with a 6H-[1]benzofuro[3,2-c]chromene skeleton and its substituted derivatives. They are the 3,4-didehydroderivatives of pterocarpans.
delta-lactoneA lactone having a six-membered lactone ring.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
coumestrol biosynthesis011
isoflavonoid biosynthesis I120

Protein Targets (73)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency32.46480.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency56.23410.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency100.00000.044717.8581100.0000AID485294
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency10.00000.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency27.00500.125919.1169125.8920AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency6.30965.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency19.10160.007215.758889.3584AID1224835; AID588342
acid sphingomyelinaseHomo sapiens (human)Potency31.622814.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency36.42610.100020.879379.4328AID588456
WRNHomo sapiens (human)Potency79.43280.168331.2583100.0000AID651768
RAR-related orphan receptor gammaMus musculus (house mouse)Potency20.39740.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency23.68900.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency32.64270.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency79.43280.031637.5844354.8130AID743255
GLS proteinHomo sapiens (human)Potency7.94330.35487.935539.8107AID624170
SMAD family member 3Homo sapiens (human)Potency23.68900.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency20.73290.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency13.65030.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency23.49430.000221.22318,912.5098AID588515; AID588516; AID743035; AID743036; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency1.49060.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency47.55240.001022.650876.6163AID1224838; AID1224839
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency30.51190.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency51.40110.000817.505159.3239AID1159527; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency57.52870.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency68.26720.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency31.17070.000229.305416,493.5996AID1259383; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency51.64560.001024.504861.6448AID588534; AID588535; AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency39.44350.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency48.67590.023723.228263.5986AID588541; AID743222
alpha-galactosidaseHomo sapiens (human)Potency31.62284.466818.391635.4813AID2107
aryl hydrocarbon receptorHomo sapiens (human)Potency42.00790.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency26.17150.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency21.85850.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency52.683519.739145.978464.9432AID1159509
Histone H2A.xCricetulus griseus (Chinese hamster)Potency64.05340.039147.5451146.8240AID1224845; AID1224896
Bloom syndrome protein isoform 1Homo sapiens (human)Potency28.18380.540617.639296.1227AID2528
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency32.90900.036619.637650.1187AID1466; AID2112; AID2242
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency50.04190.010039.53711,122.0200AID1469; AID1479; AID588545
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency2.31870.000323.4451159.6830AID743065; AID743066; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency10.05640.037617.082361.1927AID1259364; AID1259388
heat shock protein beta-1Homo sapiens (human)Potency16.66000.042027.378961.6448AID743210
DNA polymerase betaHomo sapiens (human)Potency35.48130.022421.010289.1251AID485314
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency39.81074.466824.832944.6684AID651749
flap endonuclease 1Homo sapiens (human)Potency42.23950.133725.412989.1251AID588795
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.99790.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency44.66840.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency79.43280.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency56.23410.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency16.36010.004611.374133.4983AID624296
DNA polymerase kappa isoform 1Homo sapiens (human)Potency76.11040.031622.3146100.0000AID588579
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1487
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62283.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62283.548118.039535.4813AID1466
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency62.16520.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency58.59070.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SUMO-1Homo sapiens (human)IC50 (µMol)40.65000.64707.494715.9000AID624382; AID624383
rac GTPase-activating protein 1 isoform aHomo sapiens (human)IC50 (µMol)32.34007.390057.8904301.2400AID624330
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)IC50 (µMol)12.00000.00240.31511.7700AID1153247
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.04330.00000.723732.7000AID240695; AID70199
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)42.65790.00101.979414.1600AID255211
Casein kinase II subunit alpha'Homo sapiens (human)IC50 (µMol)0.20000.00031.432010.0000AID1639195
Casein kinase II subunit alpha'Homo sapiens (human)Ki7.67000.00020.90117.6700AID1750468
Casein kinase II subunit betaHomo sapiens (human)IC50 (µMol)0.20000.00031.487510.0000AID1639195
Casein kinase II subunit betaHomo sapiens (human)Ki7.67000.00021.11247.6700AID1750468
Casein kinase II subunit alphaHomo sapiens (human)IC50 (µMol)0.20000.00051.333210.0000AID1639195
Casein kinase II subunit alphaHomo sapiens (human)Ki7.67000.00041.09847.6700AID1539764; AID1750468
Casein kinase II subunit alpha 3Homo sapiens (human)IC50 (µMol)0.20000.00151.966410.0000AID1639195
Casein kinase II subunit alpha 3Homo sapiens (human)Ki7.67000.00041.86517.6700AID1750468
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)0.01310.00010.529432.7000AID240680; AID70514
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (107)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
double-strand break repairCasein kinase II subunit alpha'Homo sapiens (human)
apoptotic processCasein kinase II subunit alpha'Homo sapiens (human)
spermatogenesisCasein kinase II subunit alpha'Homo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
cerebral cortex developmentCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alpha'Homo sapiens (human)
liver regenerationCasein kinase II subunit alpha'Homo sapiens (human)
regulation of mitophagyCasein kinase II subunit alpha'Homo sapiens (human)
positive regulation of protein targeting to mitochondrionCasein kinase II subunit alpha'Homo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
signal transductionCasein kinase II subunit betaHomo sapiens (human)
negative regulation of cell population proliferationCasein kinase II subunit betaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit betaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit betaHomo sapiens (human)
positive regulation of activin receptor signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
adiponectin-activated signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationCasein kinase II subunit betaHomo sapiens (human)
regulation of DNA bindingCasein kinase II subunit betaHomo sapiens (human)
positive regulation of SMAD protein signal transductionCasein kinase II subunit betaHomo sapiens (human)
endothelial tube morphogenesisCasein kinase II subunit betaHomo sapiens (human)
protein-containing complex assemblyCasein kinase II subunit betaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit betaHomo sapiens (human)
negative regulation of viral life cycleCasein kinase II subunit betaHomo sapiens (human)
double-strand break repairCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
DNA damage responseCasein kinase II subunit alphaHomo sapiens (human)
signal transductionCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of translationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
rhythmic processCasein kinase II subunit alphaHomo sapiens (human)
protein stabilizationCasein kinase II subunit alphaHomo sapiens (human)
chaperone-mediated protein foldingCasein kinase II subunit alphaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of aggrephagyCasein kinase II subunit alphaHomo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
regulation of cell cycleCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alpha 3Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
regulation of cell cycleCasein kinase II subunit alpha 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (47)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
protein bindingCasein kinase II subunit alpha'Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha'Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit betaHomo sapiens (human)
chromatin bindingCasein kinase II subunit betaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit betaHomo sapiens (human)
signaling receptor bindingCasein kinase II subunit betaHomo sapiens (human)
protein bindingCasein kinase II subunit betaHomo sapiens (human)
protein kinase regulator activityCasein kinase II subunit betaHomo sapiens (human)
protein domain specific bindingCasein kinase II subunit betaHomo sapiens (human)
protein-macromolecule adaptor activityCasein kinase II subunit betaHomo sapiens (human)
identical protein bindingCasein kinase II subunit betaHomo sapiens (human)
metal ion bindingCasein kinase II subunit betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCasein kinase II subunit betaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingCasein kinase II subunit alphaHomo sapiens (human)
ATP bindingCasein kinase II subunit alphaHomo sapiens (human)
kinase activityCasein kinase II subunit alphaHomo sapiens (human)
identical protein bindingCasein kinase II subunit alphaHomo sapiens (human)
Hsp90 protein bindingCasein kinase II subunit alphaHomo sapiens (human)
protein serine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha 3Homo sapiens (human)
protein bindingCasein kinase II subunit alpha 3Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha 3Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha 3Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
PcG protein complexCasein kinase II subunit alpha'Homo sapiens (human)
acrosomal vesicleCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
nucleoplasmCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha'Homo sapiens (human)
chromatinCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
plasma membraneCasein kinase II subunit betaHomo sapiens (human)
PcG protein complexCasein kinase II subunit betaHomo sapiens (human)
PML bodyCasein kinase II subunit betaHomo sapiens (human)
extracellular regionCasein kinase II subunit betaHomo sapiens (human)
nucleusCasein kinase II subunit betaHomo sapiens (human)
nucleoplasmCasein kinase II subunit betaHomo sapiens (human)
cytoplasmCasein kinase II subunit betaHomo sapiens (human)
cytosolCasein kinase II subunit betaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit betaHomo sapiens (human)
secretory granule lumenCasein kinase II subunit betaHomo sapiens (human)
extracellular exosomeCasein kinase II subunit betaHomo sapiens (human)
ficolin-1-rich granule lumenCasein kinase II subunit betaHomo sapiens (human)
chromatinCasein kinase II subunit betaHomo sapiens (human)
cytoplasmCasein kinase II subunit betaHomo sapiens (human)
PcG protein complexCasein kinase II subunit alphaHomo sapiens (human)
PML bodyCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
plasma membraneCasein kinase II subunit alphaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alphaHomo sapiens (human)
Sin3-type complexCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alpha 3Homo sapiens (human)
nucleusCasein kinase II subunit alpha 3Homo sapiens (human)
cytosolCasein kinase II subunit alpha 3Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha 3Homo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1153247Antagonist activity at human PXR transfected in African green monkey CV1 cells assessed as inhibition of SR12813-induced transactivation after 24 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Bazedoxifene-scaffold-based mimetics of solomonsterols A and B as novel pregnane X receptor antagonists.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID240680Binding affinity for human Estrogen receptor beta2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID235514Selectivity was determined as ratio of IC50 against human ER alpha to that of human ER beta2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID70199Binding affinity against human estrogen receptor alpha in competitive binding assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID1750468Inhibition of CK2 (unknown origin)
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID169069In vivo anti-estrogenic activity using an immature rat uterine weight assay.2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID1503775Antichlamydial activity against Chlamydia pneumoniae K7 infected in HL cells assessed as chlamydial inhibition at 50 uM after 70 hrs by fluorescent microscopic analysis2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID1180339Antioxidant activity assessed as AAPH-induced peroxyl radical scavenging activity by oxygen radical absorbance assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Anti-osteoporotic and antioxidant activities of chemical constituents of the aerial parts of Ducrosia ismaelis.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID240695Binding affinity for human Estrogen receptor Alpha2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
AID70514Binding affinity against human estrogen receptor beta (ER beta) in competitive binding assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID1639195Inhibition of human CK2 using HRRRDDD-SDDD-NH2 as substrate after 30 mins by ADP-Glo reagent based luminescence assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
Inhibitory Properties of ATP-Competitive Coumestrol and Boldine Are Correlated to Different Modulations of CK2 Flexibility.
AID292109Cytotoxicity against HUVEC after 24 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
In-silico fragment-based identification of novel angiogenesis inhibitors.
AID244129Selectivity for Estrogen receptors alpha and beta2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
AID1539764Inhibition of CK2alpha (unknown origin)2019European journal of medicinal chemistry, Nov-01, Volume: 181Small molecule modulators targeting protein kinase CK1 and CK2.
AID1503774Cytotoxicity against human HL cells assessed as cell viability at 50 uM after 72 hrs by resazurin dye based fluorescence assay relative to control2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (291)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (9.97)18.7374
1990's59 (20.27)18.2507
2000's84 (28.87)29.6817
2010's96 (32.99)24.3611
2020's23 (7.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.45 (24.57)
Research Supply Index5.73 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index54.12 (26.88)
Search Engine Supply Index2.10 (0.95)

This Compound (36.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.66%)5.53%
Reviews8 (2.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other295 (96.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]